Press release 📈 Stocks 🌍 Denmark

Roche Diagnostics Deploys Endotrophin Research Assay at Nordic Bioscience

Roche Diagnostics and Nordic Bioscience expand their biomarker collaboration by deploying an Endotrophin research assay on cobas e801 systems to study its role in fibrosis and cardiovascular disease.

🕐 1 min read

1 assets impacted (Stocks). Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: RO → 1/10 (60% confidence).

📊 Affected Assets (1)

RO
Neutral 🤖 60%
📅 Short-term 🌍 CH · Explicit

Roche Diagnostics is making its Endotrophin research prototype assay available on its cobas e801 analyzers at Nordic Bioscience's CLIA lab, the second biomarker from the collaboration after Elecsys PRO-C3. This is an early-stage research tool with no revenue, volume or order figures, so the financial effect on Roche shares is negligible; the press release is corporate self-description without a hard quantified fact.

🧭 Full analysis of these assets

🎯 Key Takeaways

  • Roche Diagnostics provided the Endotrophin research prototype assay for use on cobas e801 analyzers at Nordic Bioscience's CLIA lab.
  • Endotrophin has been measured in over 50,000 patients with cardio-renal-metabolic syndrome.
  • The FDA has issued a letter of support for Endotrophin as an enrichment tool in clinical trials for heart failure with preserved ejection fraction (HFpEF).
  • This is the second biomarker collaboration between the firms, following the CE-marked Elecsys PRO-C3 test.

📝 Executive Summary

Roche Diagnostics has made its Endotrophin research prototype assay available on cobas e801 analyzers at Nordic Bioscience's CLIA laboratory. This marks the second biomarker collaboration between the two companies, following the launch of Elecsys PRO-C3, and aims to advance research into fibro-inflammatory risks associated with cardio-renal-metabolic syndromes.